These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35460753)

  • 1. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.
    Li T; Zhou B; Li Y; Huang S; Luo Z; Zhou Y; Lai Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
    Int J Biol Macromol; 2022 Jun; 209(Pt A):1379-1388. PubMed ID: 35460753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
    Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
    Chen X; Gentili M; Hacohen N; Regev A
    Nat Commun; 2021 Sep; 12(1):5506. PubMed ID: 34535642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug.
    Liu Q; Lu Y; Cai C; Huang Y; Zhou L; Guan Y; Fu S; Lin Y; Yan H; Zhang Z; Li X; Yang X; Yang H; Guo H; Lan K; Chen Y; Hou SC; Xiong Y
    Cell Death Dis; 2024 Jun; 15(6):458. PubMed ID: 38937437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
    Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
    Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
    Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
    Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein.
    Zhang Y; Wang D; Xiang Q; Hu X; Zhang Y; Wu L; Zhang Z; Wang Y; Zhao J; McCormick PJ; Fu J; Fu Y; Zhang J; Jiang H; Li J
    Virology; 2024 Jan; 589():109925. PubMed ID: 37984151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
    Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of
    Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
    Elife; 2021 Aug; 10():. PubMed ID: 34338634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].
    Chen Y; Lin J; Zheng P; Cao M; Jin T
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3173-3193. PubMed ID: 36151792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
    Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
    Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.